Program
M701
A development code. Also written as “M701 pleural infusion”.
Its studies are mostly in Pleural Effusion, Malignant, led by Wuhan YZY Biopharma.
Furthest: phase 2, since Sep 14, 20221 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wuhan YZY Biopharma | 11 open or running | phase 2since Sep 14, 2022 | Sep 14, 2022 | none ahead |
- Named in sino biopharmaceutical’s own pipeline as
M701
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2022First study: phase 2 study in Pleural Effusion, MalignantFirst studyNCT05543330 · 116 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05543330Pleural Effusion, Malignant · China | 2 | Recruiting | Sep 15, 2026 | 116 |
How it is read
Names in the registry
- “M701 pleural infusion”, 1 entry
Codes read as this program: M701.
Conditions, from the studies’ own filings
- Pleural Effusion, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.